Introduction
============

In the context of a multimodal approach, including psychosocial, family and psychotherapeutic interventions, the primary treatment for bipolar disorder (BD) with onset during childhood or adolescence is pharmacological.[@b1-ndt-14-2749] First-line medications include mood stabilizers, such as lithium, valproate and carbamazepine, and atypical antipsychotics, such as aripiprazole, olanzapine, quetiapine and risperidone.[@b2-ndt-14-2749] Although risperidone showed higher response rates in bipolar adolescents, compared to both lithium and divalproex,[@b3-ndt-14-2749] growing concerns are associated with the use of atypical antipsychotics in children and adolescents.[@b4-ndt-14-2749] Lithium is currently approved by most regulatory agencies, including the Food and Drug Administration and the European Medicine Agency, for the treatment of BD adolescents older than 12 years. Although a recent double-blind, placebo-controlled study further supported the efficacy of lithium in youths with BD,[@b5-ndt-14-2749] studies reporting the efficacy of lithium in youths, namely the long-term data, are still scant.[@b6-ndt-14-2749]

Among the long-term studies, Strober et al[@b7-ndt-14-2749] reported on 37 adolescents with BD stabilized with lithium, who were naturalistically followed up for 18 months. At the end of the follow-up period, 21 patients (56.8%) relapsed, and the relapse rate was three times higher among patients who discontinued lithium earlier. Findling et al[@b8-ndt-14-2749] explored the comparative effectiveness of lithium and divalproex in the maintenance treatment of juvenile BD, over 76 weeks, without differences in time to mood relapse or treatment discontinuation. Our aim was to describe the medium-term safety and effectiveness of lithium in referred adolescent bipolar patients, who were naturalistically followed up for 8 months.

Methods
=======

Sample and measures
-------------------

This was a naturalistic study based on a clinical database of consecutive Caucasian youth, aged between 12 and 18 years, with three inclusion criteria: a *Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition-Text Revised* (DSM IV-TR) and DSM-5 diagnosis of BD, a pharmacological treatment with lithium carbonate, three follow-up points, at the baseline, after 4 months and 8 months. These time points were selected according to the routine follow-up procedures of our department. All the subjects were screened for psychiatric disorders, using historical information, a structured clinical interview according to DSM criteria, the Schedule for Affective Disorders and Schizophrenia for School-Age Children -- Present and Lifetime Version (K-SADS-PL).[@b9-ndt-14-2749] Patients with schizophrenia, autism spectrum disorder and intellectual disability were excluded. Given the naturalistic design of the study, patients receiving other pharmacological treatments were not excluded, when the dosages of other treatments were stable from at least 4 weeks before starting lithium and remained unchanged during the follow-up. Among 45 patients who started lithium, 15 patients were excluded because their clinical condition needed the stable introduction of a new medication during the follow-up. Thirty patients remained on this treatment for at least 8 months and were included in the study (18 males, mean age of 14.2±2.1 years). Seventeen patients (56.7%) presented with anxiety comorbidities, 14 (46.7%) had oppositional defiant disorder or conduct disorder and 12 (40%) had an attention-deficit hyperactivity disorder (ADHD). Seventeen patients received second generation antipsychotics (SGAs), four valproic acid, two fluoxetine and 16 concomitant psychotherapy. Although our assessment was limited to the 4th and 8th month of treatment, patients monitored their blood levels of lithium more frequently, and the available data supported the good compliance with treatment.

Our primary outcome measure was the improvement in symptoms according to the Clinical Global Impression- Severity (CGI-S) score,[@b10-ndt-14-2749] assessed at the baseline (T0), after 4 months (T1) and after 8 months (T2). Secondary outcome measure was the functional improvement assessed using the Children Global Assessment Scale (C-GAS),[@b11-ndt-14-2749] assessed at the baseline, T1 and T2. Safety data were assessed at the baseline and follow-up and included physical examination, blood cell count, blood chemistry, electrolytes, thyroid function and electrocardiogram (ECG) (including QTc interval).

All the diagnostic and therapeutic procedures, including lithium treatment, as well as the follow-up visits and data collection, were part of our routine procedures. The institutional review board of the Scientific Institute Stella Maris (Pisa) approved the study. All subjects and parents received detailed information on the assessment measures and different treatment options and gave their written informed consent to the treatment with lithium.

Statistical analyses
--------------------

A paired *t*-test was used to compare the values of continuous variables from baseline to T1 and T2. Analyses were run in SPSS Version 20 (IBM Corporation, Armonk, NY, USA).

Results
=======

Patients presented a severe baseline status (CGI-S 5.7±0.5, C-GAS 35.1±3.7). Mean lithium dosage at T1 was 843±176.6 mg/day (range 600--1,200 mg/day) and at T2 was 858±149 mg/day (range 600--1,200 mg/day). Mean blood level of lithium was 0.69±0.20 mEq/L at T1 and 0.70±0.18 mEq/L at T2. A summary of baseline characteristics of the sample and efficacy results is provided in [Table 1](#tI-ndt-14-2749){ref-type="table"}.

Regarding efficacy, CGI-S score improved from 5.7±0.53 at baseline to 4.2±0.70 at T1 (*t*=8.7, *P*\<0.001) and 4.0±0.9 at T2 (*t*=7.8, *P*\<0.001; moderately to markedly ill); from T1 to T2, the difference was not significant (*t*=1.6, *P*=0.1). Similarly, C-GAS score improved from 35.1±3.7 at baseline to 46.4±6.5 at T1 (*t*=−9.0, *P*=0.001) and 47.5±8.3 (*t*=−7.4, *P*\<0.001) at T2 (moderate impairment in most areas or severe in one area); from T1 to T2, the difference was not significant (*t*=−0.8; *P*=0.4). No patients relapsed during the follow-up. Emergence of both suicidal ideation and behavior was not reported during the entire follow-up. The presence of any group of comorbidities (anxiety disorder, disruptive behavioral disorder and ADHD) had no effect on the results.

Regarding thyroid function, thyroid-stimulating hormone (TSH) significantly increased from 2.16±1.8 mU/mL at baseline to 3.9±2.7 at T1 (*t*=−2.8, *P*=0.013) and 3.49±2.2 at T2 (*t*=−2.8; *P*=0.011), remaining within the normal range. Two patients presented a TSH level beyond 7 mU/mL at T1, and based on the significant improvement they continued on lithium receiving thyroid hormone supplementation. Thyroid hormones (T3 and T4) did not show significant changes. Mean level of T3 was 4.63±0.98 at baseline, 4.44±0.85 at T1 (*P*=not significant \[NS\]) and 4.38±1.33 at T2 (*P*=NS). Mean T4 level was 0.93±0.17 at baseline, 0.94±0.22 at T1 (*P*=NS) and 1.15±0.93 at T2 (*P*=NS).

Regarding kidney functioning, mean creatinine serum levels were 0.69±0.14 mg/dL at baseline, 0.72±0.15 mg/dL at T1 and 0.75±0.14 mg/dL at T2 (*P*=NS). No patients exceeded normal creatinine serum levels of 1.1 mg/dL. Two patients (6.4%) presented polyuria and polydipsia. Urine examination was normal for all the patients during the follow-up.

Regarding cardiac function, QTc interval at the ECG did not reveal significant changes (mean baseline QTc 416.8±30 ms, 413.2±21.2 ms at T1 and 408.2±21.2 ms at T2) (*P*=NS); no patients exceeded 450 ms.

White blood cell count revealed an increase from 6.93±1.68 10^3^/mmc at baseline to 7.30±2.00 10^3^/mmc at T1 (*P*=NS), up to 7.94±1.94 10^3^/mmc at T2 (*P*=0.032). Blood levels of calcium increased as well, from 9.68±0.3 mg/dL at baseline to 9.87±0.34 mg/dL at T1 (*P*=0.023) and 9.97±0.29 mg/dL at T2 (*P*\<0.001). Other electrolyte levels were stable during the follow-up.

The other reported side effects were early gastrointestinal symptoms (five patients, 16.7%), asthenia and sedation (three patients, 9.7%) and tremors (two patients, 6.4%), which were not required lithium discontinuation. No patients experienced skin rash. In a subset of patients, we gathered body mass index (BMI) data of the two follow-ups. At baseline, mean BMI was 18.7 (SD 3.4), at T1 20.1 (SD 3.2; *P*=NS) at T2 19.7 (SD 3; *P*=NS). No patients discontinued lithium due to excessive weight gain.

Discussion
==========

In our sample of severely impaired adolescents with BD, lithium treatment significantly improved clinical severity and functional impairment. The clinical and functional improvement occurred in the first 4 months and was confirmed in the following 4 months, without relapses. Consistently with the antisuicidal properties of lithium in mood disorders,[@b12-ndt-14-2749] emergence of both suicidal ideation and behavior was not reported during the follow-up. It is noteworthy that effective lithium blood levels were relatively low (ranging from 0.4 mEq/L to 0.8 mEq/L). Regarding safety data, treatment with lithium was well tolerated, which is in line with previous studies.[@b6-ndt-14-2749] A moderate increase in TSH was found, although two patients needed the add-on thyroid hormone supplementation. Renal function was preserved. Neither cardiac symptoms nor QTc alterations emerged during the follow-up. White blood cell count and calcium levels increased, but within the normal range and without clinical implications. Other electrolyte levels (including sodium and potassium) remained normal during the follow-up. Gastrointestinal symptoms usually occurred in the early phase of treatment, while sedation and tremor were more rarely reported during the follow-up. The rate of side effects was lower, compared to similar studies in adult populations, probably due to relatively lower blood levels of lithium in our sample of adolescents.

Our naturalistic study presents several methodological limitations. This is not a randomized, controlled study. We only gathered data from patients who completed 8 months of follow-up, and this may have biased the results in favor of better efficacy and safety. Another confusing element is that many patients received other medications, namely SGAs or valproic acid, with anti-manic properties even in mono-therapy. However, the dosage of other medications was stable from at least 4 weeks before starting lithium and remained unchanged during the follow-up. Although not supported by all guidelines, polypharmacy is the rule rather than exception in the real world of bipolar patients receiving medications. In the Bhangoo et al's[@b13-ndt-14-2749] study, youths were receiving 3.40±1.48 medications, and 77% of them had had a trial of an antipsychotic. In the Pavuluri et al's[@b14-ndt-14-2749] study, only 17.5% of bipolar youths without psychotic symptoms were effectively controlled by a monotherapy with a mood stabilizer for at least 6 months, while 66.3% of those receiving a combination of a mood stabilizer and an SGA were responders. Another relevant limitation, considering the high rate of comorbidities, is that we have used the CGI-S, CGI-I and C-GAS as outcome measures, which are not specific for manic/mixed symptoms' severity and improvement, but give an overall rating of effectiveness. An improvement in the global measure scores may have been affected by other comorbid disorders and not by a specific effect of lithium on BD. However, the CGI and C-GAS criterion corresponds to what clinicians use to determine whether to continue or interrupt a medication trial in naturalistic settings, as the course of the clinical picture as a whole is more reliably captured by a more global measure. Finally, we cannot extend our findings to longer follow-ups, as patients were subsequently monitored and cared by their own territorial facilities. In our study, all the patients were treated as needed (mono- or polypharmacy) and followed up in a routine clinical setting, and this may actually be one of the strengths of our study. Long-term naturalistic perspective studies might represent an important source of information on effectiveness and safety of treatment under ordinary clinical conditions, and the present findings are therefore of particular relevance to clinical practice in treating child and adolescent BD. In addition, the reassuring safety profile allows to speculate early intervention with lithium especially in special populations with juvenile bipolar patients, including patients who suffered from traumatic experiences,[@b15-ndt-14-2749] or those with high suicidal risk,[@b12-ndt-14-2749] or with comorbid conduct disorder and substance abuse.[@b16-ndt-14-2749]
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###### 

Summary of demographic characteristics and efficacy results

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient number   Age              Diagnosis             Comorbidity                 Mean lithium dose (mg/day)   Mean lithium blood level   Mean CGI-S                                            Mean C-GAS                                                                                                                        
  ---------------- ---------------- --------------------- --------------------------- ---------------------------- -------------------------- ----------------------------------------------------- ----------------------------------------------------- --------- ----------- ----------------------------------------------------- ----------
  30               14.2±2.1 years   BD 1: 10 (33.3%),\    Any anxiety: 17 (56.7%),\   843±176                      0.69±0.20                  5.7±0.53[a](#tfn1-ndt-14-2749){ref-type="table-fn"}   4.2±0.70[a](#tfn1-ndt-14-2749){ref-type="table-fn"}   4.0±0.9   35.1 ±3.7   46.4±6.5[a](#tfn1-ndt-14-2749){ref-type="table-fn"}   47.5±8.3
                                    BD II: 11 (36.7%),\   DBD: 14 (46.7%),\                                                                                                                                                                                                                                                           
                                    BD NOS: 9 (30.0%)     ADHD: 12 (40%)                                                                                                                                                                                                                                                              

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Statistically significant differences.

**Abbreviations:** ADHD, attention-deficit hyperactivity disorder; BD, bipolar disorder; C-GAS, Children Global Assessment Scale; CGI-S, Clinical Global Impression-Severity; DBD, disruptive behavior disorder; NOS, not otherwise specified.
